David A. Siegel Biomarin Pharmaceutical Inc Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 107,014 shares of BMRN stock, worth $7.3 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
107,014
Previous 181,314
40.98%
Holding current value
$7.3 Million
Previous $12.7 Million
44.81%
% of portfolio
0.02%
Previous 0.03%
Shares
25 transactions
Others Institutions Holding BMRN
# of Institutions
626Shares Held
183MCall Options Held
2MPut Options Held
1.67M-
Black Rock Inc. New York, NY22.7MShares$1.55 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19.4MShares$1.32 Billion0.02% of portfolio
-
Primecap Management CO Pasadena, CA18.2MShares$1.24 Billion0.94% of portfolio
-
Dodge & Cox San Francisco, CA14.7MShares$1.01 Billion0.61% of portfolio
-
Capital Research Global Investors Los Angeles, CA13MShares$887 Million0.18% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $12.7B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...